Mangoceuticals Inc（MGRX）資訊與事件MGRXMangoceuticals Inc

Mangoceuticals' Former Subsidiary Secures $2.5M Investment

Mangoceuticals announced that its former wholly-owned subsidiary, MangoRx IP Holdings, has entered into subscription agreements with two strategic investors for an aggregate investment of $2.5M directly into MangoRx IP, and has received the first tranche of $1.75M due thereunder. "Importantly, the investments are being made at the subsidiary level and do not involve the issuance of any shares of Mangoceuticals common stock, warrants or other securities of the publicly-traded parent company. Accordingly, the transactions do not increase the number of outstanding shares of Mangoceuticals or otherwise impact the Company's public capitalization structure. Under the terms of the agreements, the investors have committed to purchase an aggregate 25% membership interest in MangoRx IP for $2.5M, payable in two tranches. The initial tranche consists of the equivalent of a 17.5% membership interest on a post-acquisition basis for $1.75M, and the second tranche consists of the remaining 7.5% membership interest for $750,000, payable within 60 days following the initial closing, or by November 28, 2026, subject to the terms and conditions of the applicable subscription agreement. We believe that the investment positions MangoRx IP to pursue opportunities across the full scope of its patent portfolio, which covers oral-surface administered preparations designed to help prevent illnesses acquired through the oral cavity and pharynx," the company stated.

Mangoceuticals Enters Business Combination Agreement with Nuclea Energy

Mangoceuticals announced that it has entered into a definitive business combination agreement with Nuclea Energy, an advanced nuclear technology company founded in August 2023 and headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor. Nuclea is advancing its Morpheus nuclear reactor from the current design stage through an 18-month development roadmap toward regulatory and commercial readiness. Pursuant to the terms of the Agreement, a newly formed subsidiary of Mangoceuticals will amalgamate with Nuclea, with the resulting company continuing as an indirect wholly owned subsidiary of Mangoceuticals. In connection with the amalgamation, holders of Nuclea common shares will receive exchangeable shares of a Mangoceuticals subsidiary, exchangeable on a one-for-one basis for shares of Mangoceuticals common stock and carrying economic and voting rights intended to be substantially equivalent to those of Mangoceuticals common stock, subject to the Nasdaq Cap. Until both Mangoceuticals stockholder approval and Nasdaq approval of the initial listing application have been obtained, the aggregate economic rights, voting rights and exchange rights attributable to the Exchangeable Shares, together with any Mangoceuticals common stock issued in connection with the transaction, will be limited by a cap equal to 19.99% of the outstanding Mangoceuticals common stock immediately prior to closing. The transaction has been approved by the boards of directors of both Mangoceuticals and Nuclea. Joseph Gunnar & Co. is serving as the exclusive financial advisor for the transaction.

Mangoceuticals Sues Clarity Ventures for Over $73M

Mangoceuticals announced that it has filed a civil lawsuit against Clarity Ventures, its former technology consulting and software development firm. The lawsuit, filed in Texas state court, seeks damages exceeding $73M, exclusive of interest, costs, and attorneys' fees. The company alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource planning and e-commerce platform that Clarity had been engaged to design and implement in support of the company's operations. Clarity has denied the company's allegations and has asserted counterclaims related to alleged unpaid invoices. The company believes these counterclaims are unwarranted, as all binding and required payments under the applicable agreements were made in full prior to disengaging from Clarity's services. The company intends to pursue its claims and defend against the counterclaims through the litigation process. Following the events described in the complaint, the company independently developed and deployed a new proprietary telehealth and e-commerce platform designed to support its operations. All allegations remain subject to the litigation process and have not been proven in a court of law.